ASTRAZEN / NSE / Biotechnology & Drugs
AstraZeneca Pharma India Ltd
1Y Price Trend
Key Information
Recommendations
Target High10,653.05
Target Low7,630
Target Mean0
Target Median0
Risk Metrics
Overall RiskModerate risk
Board Risk24.84
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
AstraZeneca Pharma India closes trading window until Q1FY27 results scanx.trade
AstraZeneca Pharma India Accepts Resignations of Two Senior Executives scanx.trade
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer IndiaMedToday
AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab Indian Pharma Post
AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment Moomoo
AstraZeneca receives CDSCO approval for Trastuzumab Deruxtecan in combination with Pertuzumab for breast cancer treatment BioSpectrum India
AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu CNBC TV18
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer The Economic Times
© SharekeyX | Rusaka Technologies 2024-2026